Jean C. Emond, Robert A. Fisher, Gregory Everson, Benjamin Samstein, James J. Pomposelli, Binsheng Zhao, Sarah Forney, Kim M. Olthoff, Talia B. Baker, Brenda W. Gillespie, Robert M. Merion – 8 December 2014 – Previous reports have drawn attention to persistently decreased platelet counts among liver donors. We hypothesized an etiologic association between altered platelet counts and postdonation splenomegaly and sought to explore this relationship.

Kyung‐Suk Suh, Suk‐Won Suh, Jeong‐Moo Lee, YoungRok Choi, Nam‐Joon Yi, Kwang‐Woong Lee – 8 December 2014 – Donor safety remains an important concern in living donor liver transplantation (LDLT). In the present study, we assessed recent advancements in the donor operation for LDLT through our experience with this procedure. A total of 886 donor hepatectomies performed between January 1999 and December 2012 were analyzed.

Fiona O'Mahony, Kevin Wroblewski, Sheila M. O'Byrne, Hongfeng Jiang, Kara Clerkin, Jihane Benhammou, William S. Blaner, Simon W. Beaven – 6 December 2014 – Liver X receptors (LXRs) are determinants of hepatic stellate cell (HSC) activation and liver fibrosis. Freshly isolated HSCs from Lxrαβ−/− mice have increased lipid droplet (LD) size, but the functional consequences of this are unknown. Our aim was to determine whether LXRs link cholesterol to retinoid storage in HSCs and how this impacts activation.

Zhen‐Yu Xiao, Babak Banan, Jianluo Jia, Pamela T. Manning, Ronald R. Hiebsch, Muthukumar Gunasekaran, Gundumi A. Upadhya, William A. Frazier, Thalachallour Mohanakumar, Yiing Lin, William C. Chapman – 6 December 2014 – Orthotopic liver transplantation (OLT) remains the standard treatment option for nonresponsive liver failure. Because ischemia/reperfusion injury (IRI) is an important impediment to the success of OLT, new therapeutic strategies are needed to reduce IRI.

Raymond D. Hickey, Shennen A. Mao, Bruce Amiot, Lukkana Suksanpaisan, Amber Miller, Rebecca Nace, Jaime Glorioso, Michael K. O'Connor, Kah Whye Peng, Yasuhiro Ikeda, Stephen J. Russell, Scott L. Nyberg – 6 December 2014 – Cell transplantation is a potential treatment for the many liver disorders that are currently only curable by organ transplantation. However, one of the major limitations of hepatocyte (HC) transplantation is an inability to monitor cells longitudinally after injection.

Nikolien van de Ven, Joe Fortunak, Bryony Simmons, Nathan Ford, Graham S. Cooke, Saye Khoo, Andrew Hill – 6 December 2014 – Combinations of direct‐acting antivirals (DAAs) can cure hepatitis C virus (HCV) in the majority of treatment‐naïve patients. Mass treatment programs to cure HCV in developing countries are only feasible if the costs of treatment and laboratory diagnostics are very low. This analysis aimed to estimate minimum costs of DAA treatment and associated diagnostic monitoring.

Gin‐Ho Lo – 6 December 2014

Shirish Barve, Irina A. Kirpich, Craig. J. McClain – 6 December 2014

Stefano Romeo, Paola Dongiovanni, Salvatore Petta, Jussi Pihalajamaki, Luca Valenti – 6 December 2014

Allon Kahn, Elizabeth J. Carey, Janis E. Blair – 6 December 2014 – Recipients of liver transplantation (LT) are at increased risk for symptomatic coccidioidomycosis, primarily because of chronic immunosuppression and impaired cellular immunity. Unfortunately, no consensus exists regarding optimal posttransplant prophylaxis. In a prior study at our institution, we observed both de novo and recurrent coccidioidomycosis despite targeted antifungal prophylaxis.